---
document_datetime: 2025-07-15 09:07:42
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/scenesse-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: scenesse-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.2973935
conversion_datetime: 2025-12-27 09:43:55.366511
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## SCENESSE

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                          |
|----------------------|------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|--------------------------------------------------|
| Variation type II /  | C.I HUMAN AND VETERINARY MEDICINAL | 05/06/2025                          |                                             | SmPC and PL                      | Please refer to Scientific Discussion 'SCENESSE- |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000247271                          | PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of sections 4.4 and 4.8 of the SmPC in order to include a warning on hypersensitivity reactions and the risk of 'anaphylactic reactions' based on post- marketing data and literature. The Package Leaflet is updated accordingly. The RMP version 9.16 has also been submitted.   |            | EMA/VR/0000247271'. A warning on hypersensitivity reactions had been added in section 4.4 of the SmPC. 'Anaphylaxis' has also been added as an adverse reaction with frequency 'uncommon' in section 4.8 of the SmPC. SmPC new text Hypersensitivity Uncommon occurrences of hypersensitivity reactions, including anaphylaxis, have been reported following administration of SCENESSE. Appropriate medical support measures should be readily available when SCENESSE is administered. If a serious hypersensitivity reaction occurs, appropriate medical treatment should be initiated, the implant should be removed if needed and further treatment with SCENESSE should be discontinued (see section 4.8). For more information, please refer to the Summary of Product Characteristics.   |
|--------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Annual reassessment - H / EMA/S/0000245110 | 10th annual re-assessment                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 22/05/2025 | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of SCENESSE should be maintained.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |